Toll Free: 1-888-928-9744

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 138 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016', provides in depth analysis on Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
- The report reviews Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Overview 10 Therapeutics Development 11 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Stage of Development 11 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Therapy Area 12 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Indication 13 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Companies 17 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Universities/Institutes 24 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Therapeutics Assessment 26 Assessment by Monotherapy/Combination Products 26 Assessment by Mechanism of Action 27 Assessment by Route of Administration 28 Assessment by Molecule Type 29 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Companies Involved in Therapeutics Development 31 AbbVie Inc. 31 Advinus Therapeutics Ltd 33 ArQule, Inc. 34 BeiGene, Ltd. 35 Bristol-Myers Squibb Company 36 Celgene Corporation 37 CrystalGenomics, Inc. 38 Genentech, Inc. 39 Hanmi Pharmaceuticals, Co. Ltd. 40 LSK BioPartners, Inc. 41 Merck KGaA 42 Ono Pharmaceutical Co., Ltd. 43 Pharmacyclics, Inc. 44 Principia Biopharma Inc. 45 Redx Pharma Plc 46 Simcere Pharmaceutical Group 47 Sunesis Pharmaceuticals, Inc. 48 Takeda Pharmaceutical Company Limited 49 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Drug Profiles 50 acalabrutinib - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 ARQ-531 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 BGB-3111 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 CG-026806 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 CG-036806 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Drug to Inhibit BTK for Undisclosed Indications - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 EBI-1266 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 EBI-1367 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 HCI-1401 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 HCI-1684 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 HM-71224 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 ibrutinib - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 M-2951 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 M-7583 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 ONO-4059 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 PLS-123 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 PNQ-154 - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 PNQ-849 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 PRN-1008 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 PRN-473 - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 RDX-002 - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 RG-7845 - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Small Molecule to Inhibit Bruton Tyrosine Kinase for Inflammation - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Small Molecule to Inhibit BTK for Immunology - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 Small Molecule to Inhibit BTK for Oncology - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 Small Molecules to Inhibit BTK for Oncology - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 Small Molecules to Inhibit BTK for Rheumatoid Arthritis - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 SNS-062 - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 spebrutinib besylate - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 TAK-020 - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 X-022 - Drug Profile 116 Product Description 116 Mechanism Of Action 116 R&D Progress 116 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Dormant Projects 117 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Discontinued Products 120 Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Featured News & Press Releases 121 Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting 121 Jun 01, 2016: NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund 123 May 31, 2016: Janssen's IMBRUVICA (ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia 124 May 24, 2016: REDX PHARMA: Proof of concept with key oncology lead 125 May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 125 May 18, 2016: Janssen to Present Data on Ibrutinib at the 2016 American Society of Clinical Oncology Annual Meeting 126 May 12, 2016: Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstroms Macroglobulinemia 127 May 09, 2016: U.S. FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia and New Indication for Small Lymphocytic Lymphoma Patients 128 Apr 29, 2016: European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients 130 Apr 29, 2016: Janssen's IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients 131 Mar 23, 2016: Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 132 Mar 14, 2016: Diplomat Now Dispensing IMBRUVICA as First-Line Therapy for Chronic Lymphocytic Leukemia 132 Mar 07, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 133 Mar 04, 2016: U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia 133 Feb 25, 2016: Acalabrutinib recommended for orphan drug designation in Europe for three indications 135 Appendix 137 Methodology 137 Coverage 137 Secondary Research 137 Primary Research 137 Expert Panel Validation 137 Contact Us 137 Disclaimer 138
List of Tables
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Development by Companies, H1 2016 (Contd..2) 20 Products under Development by Companies, H1 2016 (Contd..3) 21 Products under Development by Companies, H1 2016 (Contd..4) 22 Products under Development by Companies, H1 2016 (Contd..5) 23 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Products under Investigation by Universities/Institutes, H1 2016 25 Assessment by Monotherapy/Combination Products, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Pipeline by AbbVie Inc., H1 2016 31 Pipeline by Advinus Therapeutics Ltd, H1 2016 33 Pipeline by ArQule, Inc., H1 2016 34 Pipeline by BeiGene, Ltd., H1 2016 35 Pipeline by Bristol-Myers Squibb Company, H1 2016 36 Pipeline by Celgene Corporation, H1 2016 37 Pipeline by CrystalGenomics, Inc., H1 2016 38 Pipeline by Genentech, Inc., H1 2016 39 Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 40 Pipeline by LSK BioPartners, Inc., H1 2016 41 Pipeline by Merck KGaA, H1 2016 42 Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 43 Pipeline by Pharmacyclics, Inc., H1 2016 44 Pipeline by Principia Biopharma Inc., H1 2016 45 Pipeline by Redx Pharma Plc, H1 2016 46 Pipeline by Simcere Pharmaceutical Group, H1 2016 47 Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016 48 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 49 Dormant Projects, H1 2016 117 Dormant Projects (Contd..1), H1 2016 118 Dormant Projects (Contd..2), H1 2016 119 Discontinued Products, H1 2016 120


List of Figures
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Top 10 Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 26 Number of Products by Stage and Mechanism of Actions, H1 2016 27 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 29

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiency

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify